Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Aluminum hydroxide, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 5
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: Neuroblastoma
Interventions: β-glucan, GM-CSF, OPT-821; Dietary Supplement · Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Cancer
Interventions: AutoSynVax™ vaccine; Biological
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Miami, Florida • Columbus, Ohio

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: ACC-001 (vanutide cridificar); Biological
Lead sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more

Conditions: Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline; Biological · Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 65 Years to 100 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: B Cell Lymphoma, Follicular Lymphoma, Neoplasm
Interventions: Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Pancreas Cancer
Interventions: TG01 Vaccine, QS-21, Balstilimab; Biological · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more

Conditions: Fallopian Tubes, Ovarian Cancer, Peritoneal Cancer
Interventions: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: GM2-KLH vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor, Adult
Interventions: ASV® AGEN2017 + QS-21 Stimulon® adjuvant; Biological
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: MUC1-KLH conjugate vaccine, MUC1-KLH vaccine/QS21, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza Prevention, Pandemic Influenza Prevention
Interventions: VRC-FLUMOS0122-00-VP, ALFQ; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: MUC1-KLH vaccine/QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease
Interventions: ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 27
States / cities: Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more

Conditions: Leukemia
Interventions: QS21, bcr-abl peptide vaccine; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions: OPT-821 (QS-21), oral β-glucan; Biological · Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer
Interventions: QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

Phase 1a Study to Evaluate Immunogenicity of ASV®

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

Vaccine Therapy in Treating Patients With Breast Cancer

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence